News


Kymab appoints Dr Arndt Schottelius as Executive Vice President Research & Development

Kymab Group Limited (“Kymab”), a leading human monoclonal antibody biopharmaceutical group, announced today the appointment of Dr Arndt Schottelius as its first Executive Vice President Research & Development. Dr Schottelius will lead the Research and Development activities, including pre-clinical and clinical developments of Kymab’s expanding therapeutic antibody portfolio. The appointment will take effect in May 2017.